AustralieFrV1, Istex, Corpus, bibRecord, 000F76

von Willebrand disease: laboratory aspects of diagnosis and treatment

Identifieur interne : 000F76 ( Istex/Corpus ); précédent : 000F75; suivant : 000F77

von Willebrand disease: laboratory aspects of diagnosis and treatment

Auteurs : E. J. Favaloro ; D. Lillicrap ; M. A. Lazzari ; M. Cattaneo ; C. Mazurier ; A. Woods ; S. Meschengieser ; A. Blanco ; A. C. Kempfer ; A. Hubbard ; A. Chang

Source :

Haemophilia [ 1351-8216 ] ; 2004-10.

RBID : ISTEX:5380B00AA14E1F9E62415DC83D19AA5A8F69EBA5

English descriptors

Abstract

Summary. von Willebrand disease is the most common inherited bleeding disorder in humans. VWD can be classified into three major types, designated Types 1, 2 and 3; Type 2 can be further separated into subtypes 2A, 2B, 2M and 2N. The diagnosis of VWD requires a personal and family history of bleeding and confirmation by laboratory analysis. Although Types 2 and 3 are relatively straightforward to diagnose, there may be a risk of overdiagnosis of Type 1 because of an overlap within the normal range. We also report on the clinical profile and diagnosis of VWD in a South American cohort of patients and on the in vitro characteristics of some factor concentrates available for treatment of VWD.

Url:

https://api.istex.fr/document/5380B00AA14E1F9E62415DC83D19AA5A8F69EBA5/fulltext/pdf

DOI: 10.1111/j.1365-2516.2004.00979.x

Links to Exploration step

ISTEX:5380B00AA14E1F9E62415DC83D19AA5A8F69EBA5

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">von Willebrand disease: laboratory aspects of diagnosis and treatment</title>
<author><name sortKey="Favaloro, E J" sort="Favaloro, E J" uniqKey="Favaloro E" first="E. J." last="Favaloro">E. J. Favaloro</name>
<affiliation><mods:affiliation>*Institute of Clinical Pathology and Medical Research, Australia; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France; ††National Institute for Biological Standards and Control, UK, and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Lillicrap, D" sort="Lillicrap, D" uniqKey="Lillicrap D" first="D." last="Lillicrap">D. Lillicrap</name>
<affiliation><mods:affiliation>*Institute of Clinical Pathology and Medical Research, Australia; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France; ††National Institute for Biological Standards and Control, UK, and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Lazzari, M A" sort="Lazzari, M A" uniqKey="Lazzari M" first="M. A." last="Lazzari">M. A. Lazzari</name>
<affiliation><mods:affiliation>*Institute of Clinical Pathology and Medical Research, Australia; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France; ††National Institute for Biological Standards and Control, UK, and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Cattaneo, M" sort="Cattaneo, M" uniqKey="Cattaneo M" first="M." last="Cattaneo">M. Cattaneo</name>
<affiliation><mods:affiliation>*Institute of Clinical Pathology and Medical Research, Australia; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France; ††National Institute for Biological Standards and Control, UK, and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Mazurier, C" sort="Mazurier, C" uniqKey="Mazurier C" first="C." last="Mazurier">C. Mazurier</name>
<affiliation><mods:affiliation>*Institute of Clinical Pathology and Medical Research, Australia; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France; ††National Institute for Biological Standards and Control, UK, and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Woods, A" sort="Woods, A" uniqKey="Woods A" first="A." last="Woods">A. Woods</name>
<affiliation><mods:affiliation>*Institute of Clinical Pathology and Medical Research, Australia; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France; ††National Institute for Biological Standards and Control, UK, and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Meschengieser, S" sort="Meschengieser, S" uniqKey="Meschengieser S" first="S." last="Meschengieser">S. Meschengieser</name>
<affiliation><mods:affiliation>*Institute of Clinical Pathology and Medical Research, Australia; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France; ††National Institute for Biological Standards and Control, UK, and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Blanco, A" sort="Blanco, A" uniqKey="Blanco A" first="A." last="Blanco">A. Blanco</name>
<affiliation><mods:affiliation>*Institute of Clinical Pathology and Medical Research, Australia; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France; ††National Institute for Biological Standards and Control, UK, and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Kempfer, A C" sort="Kempfer, A C" uniqKey="Kempfer A" first="A. C." last="Kempfer">A. C. Kempfer</name>
<affiliation><mods:affiliation>*Institute of Clinical Pathology and Medical Research, Australia; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France; ††National Institute for Biological Standards and Control, UK, and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Hubbard, A" sort="Hubbard, A" uniqKey="Hubbard A" first="A." last="Hubbard">A. Hubbard</name>
<affiliation><mods:affiliation>*Institute of Clinical Pathology and Medical Research, Australia; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France; ††National Institute for Biological Standards and Control, UK, and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Chang, A" sort="Chang, A" uniqKey="Chang A" first="A." last="Chang">A. Chang</name>
<affiliation><mods:affiliation>*Institute of Clinical Pathology and Medical Research, Australia; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France; ††National Institute for Biological Standards and Control, UK, and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA</mods:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:5380B00AA14E1F9E62415DC83D19AA5A8F69EBA5</idno>
<date when="2004" year="2004">2004</date>
<idno type="doi">10.1111/j.1365-2516.2004.00979.x</idno>
<idno type="url">https://api.istex.fr/document/5380B00AA14E1F9E62415DC83D19AA5A8F69EBA5/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000F76</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000F76</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main">von Willebrand disease: laboratory aspects of diagnosis and treatment</title>
<author><name sortKey="Favaloro, E J" sort="Favaloro, E J" uniqKey="Favaloro E" first="E. J." last="Favaloro">E. J. Favaloro</name>
<affiliation><mods:affiliation>*Institute of Clinical Pathology and Medical Research, Australia; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France; ††National Institute for Biological Standards and Control, UK, and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Lillicrap, D" sort="Lillicrap, D" uniqKey="Lillicrap D" first="D." last="Lillicrap">D. Lillicrap</name>
<affiliation><mods:affiliation>*Institute of Clinical Pathology and Medical Research, Australia; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France; ††National Institute for Biological Standards and Control, UK, and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Lazzari, M A" sort="Lazzari, M A" uniqKey="Lazzari M" first="M. A." last="Lazzari">M. A. Lazzari</name>
<affiliation><mods:affiliation>*Institute of Clinical Pathology and Medical Research, Australia; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France; ††National Institute for Biological Standards and Control, UK, and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Cattaneo, M" sort="Cattaneo, M" uniqKey="Cattaneo M" first="M." last="Cattaneo">M. Cattaneo</name>
<affiliation><mods:affiliation>*Institute of Clinical Pathology and Medical Research, Australia; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France; ††National Institute for Biological Standards and Control, UK, and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Mazurier, C" sort="Mazurier, C" uniqKey="Mazurier C" first="C." last="Mazurier">C. Mazurier</name>
<affiliation><mods:affiliation>*Institute of Clinical Pathology and Medical Research, Australia; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France; ††National Institute for Biological Standards and Control, UK, and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Woods, A" sort="Woods, A" uniqKey="Woods A" first="A." last="Woods">A. Woods</name>
<affiliation><mods:affiliation>*Institute of Clinical Pathology and Medical Research, Australia; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France; ††National Institute for Biological Standards and Control, UK, and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Meschengieser, S" sort="Meschengieser, S" uniqKey="Meschengieser S" first="S." last="Meschengieser">S. Meschengieser</name>
<affiliation><mods:affiliation>*Institute of Clinical Pathology and Medical Research, Australia; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France; ††National Institute for Biological Standards and Control, UK, and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Blanco, A" sort="Blanco, A" uniqKey="Blanco A" first="A." last="Blanco">A. Blanco</name>
<affiliation><mods:affiliation>*Institute of Clinical Pathology and Medical Research, Australia; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France; ††National Institute for Biological Standards and Control, UK, and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Kempfer, A C" sort="Kempfer, A C" uniqKey="Kempfer A" first="A. C." last="Kempfer">A. C. Kempfer</name>
<affiliation><mods:affiliation>*Institute of Clinical Pathology and Medical Research, Australia; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France; ††National Institute for Biological Standards and Control, UK, and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Hubbard, A" sort="Hubbard, A" uniqKey="Hubbard A" first="A." last="Hubbard">A. Hubbard</name>
<affiliation><mods:affiliation>*Institute of Clinical Pathology and Medical Research, Australia; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France; ††National Institute for Biological Standards and Control, UK, and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Chang, A" sort="Chang, A" uniqKey="Chang A" first="A." last="Chang">A. Chang</name>
<affiliation><mods:affiliation>*Institute of Clinical Pathology and Medical Research, Australia; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France; ††National Institute for Biological Standards and Control, UK, and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA</mods:affiliation>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">Haemophilia</title>
<title level="j" type="alt">HAEMOPHILIA</title>
<idno type="ISSN">1351-8216</idno>
<idno type="eISSN">1365-2516</idno>
<imprint><biblScope unit="vol">10</biblScope>
<biblScope unit="page" from="164">164</biblScope>
<biblScope unit="page" to="168">168</biblScope>
<biblScope unit="page-count">5</biblScope>
<publisher>Blackwell Publishing Ltd</publisher>
<pubPlace>Oxford, UK</pubPlace>
<date type="published" when="2004-10">2004-10</date>
</imprint>
<idno type="ISSN">1351-8216</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">1351-8216</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Assay</term>
<term>Blackwell publishing</term>
<term>Blood group</term>
<term>Caesarean section</term>
<term>Clinical pathology</term>
<term>Collagen binding</term>
<term>Excessive mucocutaneous</term>
<term>Family history</term>
<term>Favaloro</term>
<term>Fviii</term>
<term>Fviii level</term>
<term>Fviii levels</term>
<term>Genetic analysis</term>
<term>Haemophilia</term>
<term>Inadequate response</term>
<term>Laboratoire francais</term>
<term>Laboratory aspects</term>
<term>Medical research</term>
<term>Menstrual cycle</term>
<term>Platelet</term>
<term>Possible type</term>
<term>Quantitative defect</term>
<term>Severe type</term>
<term>Thromb haemost</term>
<term>Willebrand</term>
<term>Willebrand disease</term>
<term>Willebrand factor</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en"><term>Assay</term>
<term>Blackwell publishing</term>
<term>Blood group</term>
<term>Caesarean section</term>
<term>Clinical pathology</term>
<term>Collagen binding</term>
<term>Excessive mucocutaneous</term>
<term>Family history</term>
<term>Favaloro</term>
<term>Fviii</term>
<term>Fviii level</term>
<term>Fviii levels</term>
<term>Genetic analysis</term>
<term>Haemophilia</term>
<term>Inadequate response</term>
<term>Laboratoire francais</term>
<term>Laboratory aspects</term>
<term>Medical research</term>
<term>Menstrual cycle</term>
<term>Platelet</term>
<term>Possible type</term>
<term>Quantitative defect</term>
<term>Severe type</term>
<term>Thromb haemost</term>
<term>Willebrand</term>
<term>Willebrand disease</term>
<term>Willebrand factor</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract">Summary.  von Willebrand disease is the most common inherited bleeding disorder in humans. VWD can be classified into three major types, designated Types 1, 2 and 3; Type 2 can be further separated into subtypes 2A, 2B, 2M and 2N. The diagnosis of VWD requires a personal and family history of bleeding and confirmation by laboratory analysis. Although Types 2 and 3 are relatively straightforward to diagnose, there may be a risk of overdiagnosis of Type 1 because of an overlap within the normal range. We also report on the clinical profile and diagnosis of VWD in a South American cohort of patients and on the in vitro characteristics of some factor concentrates available for treatment of VWD.</div>
</front>
</TEI>
<istex><corpusName>wiley</corpusName>
<keywords><teeft><json:string>willebrand</json:string>
<json:string>fviii</json:string>
<json:string>willebrand factor</json:string>
<json:string>willebrand disease</json:string>
<json:string>platelet</json:string>
<json:string>haemophilia</json:string>
<json:string>favaloro</json:string>
<json:string>blackwell publishing</json:string>
<json:string>thromb haemost</json:string>
<json:string>blood group</json:string>
<json:string>family history</json:string>
<json:string>assay</json:string>
<json:string>laboratory aspects</json:string>
<json:string>fviii levels</json:string>
<json:string>possible type</json:string>
<json:string>excessive mucocutaneous</json:string>
<json:string>clinical pathology</json:string>
<json:string>severe type</json:string>
<json:string>fviii level</json:string>
<json:string>quantitative defect</json:string>
<json:string>genetic analysis</json:string>
<json:string>menstrual cycle</json:string>
<json:string>medical research</json:string>
<json:string>inadequate response</json:string>
<json:string>caesarean section</json:string>
<json:string>collagen binding</json:string>
<json:string>laboratoire francais</json:string>
</teeft>
</keywords>
<author><json:item><name>E. J. Favaloro</name>
<affiliations><json:string>*Institute of Clinical Pathology and Medical Research, Australia; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France; ††National Institute for Biological Standards and Control, UK, and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA</json:string>
</affiliations>
</json:item>
<json:item><name>D. Lillicrap</name>
<affiliations><json:string>*Institute of Clinical Pathology and Medical Research, Australia; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France; ††National Institute for Biological Standards and Control, UK, and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA</json:string>
</affiliations>
</json:item>
<json:item><name>M. A. Lazzari</name>
<affiliations><json:string>*Institute of Clinical Pathology and Medical Research, Australia; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France; ††National Institute for Biological Standards and Control, UK, and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA</json:string>
</affiliations>
</json:item>
<json:item><name>M. Cattaneo</name>
<affiliations><json:string>*Institute of Clinical Pathology and Medical Research, Australia; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France; ††National Institute for Biological Standards and Control, UK, and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA</json:string>
</affiliations>
</json:item>
<json:item><name>C. Mazurier</name>
<affiliations><json:string>*Institute of Clinical Pathology and Medical Research, Australia; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France; ††National Institute for Biological Standards and Control, UK, and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA</json:string>
</affiliations>
</json:item>
<json:item><name>A. Woods</name>
<affiliations><json:string>*Institute of Clinical Pathology and Medical Research, Australia; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France; ††National Institute for Biological Standards and Control, UK, and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA</json:string>
</affiliations>
</json:item>
<json:item><name>S. Meschengieser</name>
<affiliations><json:string>*Institute of Clinical Pathology and Medical Research, Australia; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France; ††National Institute for Biological Standards and Control, UK, and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA</json:string>
</affiliations>
</json:item>
<json:item><name>A. Blanco</name>
<affiliations><json:string>*Institute of Clinical Pathology and Medical Research, Australia; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France; ††National Institute for Biological Standards and Control, UK, and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA</json:string>
</affiliations>
</json:item>
<json:item><name>A. C. Kempfer</name>
<affiliations><json:string>*Institute of Clinical Pathology and Medical Research, Australia; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France; ††National Institute for Biological Standards and Control, UK, and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA</json:string>
</affiliations>
</json:item>
<json:item><name>A. Hubbard</name>
<affiliations><json:string>*Institute of Clinical Pathology and Medical Research, Australia; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France; ††National Institute for Biological Standards and Control, UK, and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA</json:string>
</affiliations>
</json:item>
<json:item><name>A. Chang</name>
<affiliations><json:string>*Institute of Clinical Pathology and Medical Research, Australia; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France; ††National Institute for Biological Standards and Control, UK, and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA</json:string>
</affiliations>
</json:item>
</author>
<subject><json:item><lang><json:string>eng</json:string>
</lang>
<value>factor concentrate</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>diagnosis</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>treatment</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>von Willebrand disease</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>von Willebrand factor</value>
</json:item>
</subject>
<articleId><json:string>HAE979</json:string>
</articleId>
<arkIstex>ark:/67375/WNG-CTNWQQNB-F</arkIstex>
<language><json:string>eng</json:string>
</language>
<originalGenre><json:string>article</json:string>
</originalGenre>
<abstract>Summary.  von Willebrand disease is the most common inherited bleeding disorder in humans. VWD can be classified into three major types, designated Types 1, 2 and 3; Type 2 can be further separated into subtypes 2A, 2B, 2M and 2N. The diagnosis of VWD requires a personal and family history of bleeding and confirmation by laboratory analysis. Although Types 2 and 3 are relatively straightforward to diagnose, there may be a risk of overdiagnosis of Type 1 because of an overlap within the normal range. We also report on the clinical profile and diagnosis of VWD in a South American cohort of patients and on the in vitro characteristics of some factor concentrates available for treatment of VWD.</abstract>
<qualityIndicators><score>6.241</score>
<pdfWordCount>2825</pdfWordCount>
<pdfCharCount>17485</pdfCharCount>
<pdfVersion>1.4</pdfVersion>
<pdfPageCount>5</pdfPageCount>
<pdfPageSize>595 x 782 pts</pdfPageSize>
<refBibsNative>true</refBibsNative>
<abstractWordCount>118</abstractWordCount>
<abstractCharCount>699</abstractCharCount>
<keywordCount>5</keywordCount>
</qualityIndicators>
<title>von Willebrand disease: laboratory aspects of diagnosis and treatment</title>
<pmid><json:string>15479392</json:string>
</pmid>
<genre><json:string>article</json:string>
</genre>
<host><title>Haemophilia</title>
<language><json:string>unknown</json:string>
</language>
<doi><json:string>10.1111/(ISSN)1365-2516</json:string>
</doi>
<issn><json:string>1351-8216</json:string>
</issn>
<eissn><json:string>1365-2516</json:string>
</eissn>
<publisherId><json:string>HAE</json:string>
</publisherId>
<volume>10</volume>
<pages><first>164</first>
<last>168</last>
<total>5</total>
</pages>
<genre><json:string>journal</json:string>
</genre>
</host>
<namedEntities><unitex><date><json:string>2004</json:string>
</date>
<geogName></geogName>
<orgName><json:string>National Institute for Biological</json:string>
<json:string>Richardson Laboratory, Queen</json:string>
<json:string>Department of Pathology and Molecular Medicine</json:string>
<json:string>–Department of Preclinical Development, Laboratoire Francais</json:string>
<json:string>Biologics Evaluation and Research, Food and Drug</json:string>
<json:string>ICPMR</json:string>
<json:string>University of Milano</json:string>
<json:string>Blackwell Publishing Ltd</json:string>
<json:string>Institute of Clinical Pathology and Medical Research</json:string>
<json:string>LABORATORY ASPECTS TO DIAGNOSIS AND TREATMENT</json:string>
</orgName>
<orgName_funder></orgName_funder>
<orgName_provider></orgName_provider>
<persName></persName>
<placeName><json:string>San Paolo</json:string>
<json:string>Australia</json:string>
<json:string>UK</json:string>
<json:string>Argentina</json:string>
<json:string>American</json:string>
<json:string>America</json:string>
<json:string>France</json:string>
<json:string>Italy</json:string>
</placeName>
<ref_url></ref_url>
<ref_bibl><json:string>[6]</json:string>
<json:string>[11]</json:string>
<json:string>[10]</json:string>
<json:string>[8,9]</json:string>
<json:string>[3]</json:string>
<json:string>[1, 2]</json:string>
<json:string>[15]</json:string>
<json:string>[12,13]</json:string>
<json:string>[7]</json:string>
<json:string>Westmead Hospital, Westmead NSW, 2145</json:string>
<json:string>[14]</json:string>
<json:string>[4,5]</json:string>
</ref_bibl>
<bibl></bibl>
</unitex>
</namedEntities>
<ark><json:string>ark:/67375/WNG-CTNWQQNB-F</json:string>
</ark>
<categories><wos><json:string>1 - science</json:string>
<json:string>2 - hematology</json:string>
</wos>
<scienceMetrix><json:string>1 - health sciences</json:string>
<json:string>2 - clinical medicine</json:string>
<json:string>3 - cardiovascular system & hematology</json:string>
</scienceMetrix>
<scopus><json:string>1 - Health Sciences</json:string>
<json:string>2 - Medicine</json:string>
<json:string>3 - Genetics(clinical)</json:string>
<json:string>1 - Health Sciences</json:string>
<json:string>2 - Medicine</json:string>
<json:string>3 - Hematology</json:string>
<json:string>1 - Health Sciences</json:string>
<json:string>2 - Medicine</json:string>
<json:string>3 - General Medicine</json:string>
</scopus>
</categories>
<publicationDate>2004</publicationDate>
<copyrightDate>2004</copyrightDate>
<doi><json:string>10.1111/j.1365-2516.2004.00979.x</json:string>
</doi>
<id>5380B00AA14E1F9E62415DC83D19AA5A8F69EBA5</id>
<score>1</score>
<fulltext><json:item><extension>pdf</extension>
<original>true</original>
<mimetype>application/pdf</mimetype>
<uri>https://api.istex.fr/document/5380B00AA14E1F9E62415DC83D19AA5A8F69EBA5/fulltext/pdf</uri>
</json:item>
<json:item><extension>zip</extension>
<original>false</original>
<mimetype>application/zip</mimetype>
<uri>https://api.istex.fr/document/5380B00AA14E1F9E62415DC83D19AA5A8F69EBA5/fulltext/zip</uri>
</json:item>
<istex:fulltextTEI uri="https://api.istex.fr/document/5380B00AA14E1F9E62415DC83D19AA5A8F69EBA5/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">von Willebrand disease: laboratory aspects of diagnosis and treatment</title>
</titleStmt>
<publicationStmt><authority>ISTEX</authority>
<publisher>Blackwell Publishing Ltd</publisher>
<pubPlace>Oxford, UK</pubPlace>
<date type="published" when="2004-10"></date>
</publicationStmt>
<notesStmt><note type="content-type" subtype="article" source="article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</note>
<note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note>
</notesStmt>
<sourceDesc><biblStruct type="article"><analytic><title level="a" type="main">von Willebrand disease: laboratory aspects of diagnosis and treatment</title>
<title level="a" type="short">VWD: LABORATORY ASPECTS TO DIAGNOSIS AND TREATMENT</title>
<author xml:id="author-0000"><persName><forename type="first">E. J.</forename>
<surname>Favaloro</surname>
</persName>
<affiliation>*Institute of Clinical Pathology and Medical Research, Australia ; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada ; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina ; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy ; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France ; ††National Institute for Biological Standards and Control, UK , and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA<address><country key="US"></country>
</address>
</affiliation>
</author>
<author xml:id="author-0001"><persName><forename type="first">D.</forename>
<surname>Lillicrap</surname>
</persName>
<affiliation>*Institute of Clinical Pathology and Medical Research, Australia ; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada ; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina ; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy ; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France ; ††National Institute for Biological Standards and Control, UK , and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA<address><country key="US"></country>
</address>
</affiliation>
</author>
<author xml:id="author-0002"><persName><forename type="first">M. A.</forename>
<surname>Lazzari</surname>
</persName>
<affiliation>*Institute of Clinical Pathology and Medical Research, Australia ; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada ; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina ; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy ; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France ; ††National Institute for Biological Standards and Control, UK , and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA<address><country key="US"></country>
</address>
</affiliation>
</author>
<author xml:id="author-0003"><persName><forename type="first">M.</forename>
<surname>Cattaneo</surname>
</persName>
<affiliation>*Institute of Clinical Pathology and Medical Research, Australia ; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada ; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina ; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy ; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France ; ††National Institute for Biological Standards and Control, UK , and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA<address><country key="US"></country>
</address>
</affiliation>
</author>
<author xml:id="author-0004"><persName><forename type="first">C.</forename>
<surname>Mazurier</surname>
</persName>
<affiliation>*Institute of Clinical Pathology and Medical Research, Australia ; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada ; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina ; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy ; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France ; ††National Institute for Biological Standards and Control, UK , and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA<address><country key="US"></country>
</address>
</affiliation>
</author>
<author xml:id="author-0005"><persName><forename type="first">A.</forename>
<surname>Woods</surname>
</persName>
<affiliation>*Institute of Clinical Pathology and Medical Research, Australia ; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada ; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina ; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy ; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France ; ††National Institute for Biological Standards and Control, UK , and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA<address><country key="US"></country>
</address>
</affiliation>
</author>
<author xml:id="author-0006"><persName><forename type="first">S.</forename>
<surname>Meschengieser</surname>
</persName>
<affiliation>*Institute of Clinical Pathology and Medical Research, Australia ; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada ; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina ; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy ; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France ; ††National Institute for Biological Standards and Control, UK , and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA<address><country key="US"></country>
</address>
</affiliation>
</author>
<author xml:id="author-0007"><persName><forename type="first">A.</forename>
<surname>Blanco</surname>
</persName>
<affiliation>*Institute of Clinical Pathology and Medical Research, Australia ; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada ; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina ; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy ; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France ; ††National Institute for Biological Standards and Control, UK , and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA<address><country key="US"></country>
</address>
</affiliation>
</author>
<author xml:id="author-0008"><persName><forename type="first">A. C.</forename>
<surname>Kempfer</surname>
</persName>
<affiliation>*Institute of Clinical Pathology and Medical Research, Australia ; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada ; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina ; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy ; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France ; ††National Institute for Biological Standards and Control, UK , and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA<address><country key="US"></country>
</address>
</affiliation>
</author>
<author xml:id="author-0009"><persName><forename type="first">A.</forename>
<surname>Hubbard</surname>
</persName>
<affiliation>*Institute of Clinical Pathology and Medical Research, Australia ; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada ; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina ; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy ; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France ; ††National Institute for Biological Standards and Control, UK , and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA<address><country key="US"></country>
</address>
</affiliation>
</author>
<author xml:id="author-0010"><persName><forename type="first">A.</forename>
<surname>Chang</surname>
</persName>
<affiliation>*Institute of Clinical Pathology and Medical Research, Australia ; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada ; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina ; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy ; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France ; ††National Institute for Biological Standards and Control, UK , and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA<address><country key="US"></country>
</address>
</affiliation>
</author>
<idno type="istex">5380B00AA14E1F9E62415DC83D19AA5A8F69EBA5</idno>
<idno type="ark">ark:/67375/WNG-CTNWQQNB-F</idno>
<idno type="DOI">10.1111/j.1365-2516.2004.00979.x</idno>
<idno type="unit">HAE979</idno>
<idno type="toTypesetVersion">file:HAE.HAE979.pdf</idno>
</analytic>
<monogr><title level="j" type="main">Haemophilia</title>
<title level="j" type="alt">HAEMOPHILIA</title>
<idno type="pISSN">1351-8216</idno>
<idno type="eISSN">1365-2516</idno>
<idno type="book-DOI">10.1111/(ISSN)1365-2516</idno>
<idno type="book-part-DOI">10.1111/hae.2004.10.issue-s4</idno>
<idno type="product">HAE</idno>
<idno type="publisherDivision">ST</idno>
<imprint><biblScope unit="vol">10</biblScope>
<biblScope unit="page" from="164">164</biblScope>
<biblScope unit="page" to="168">168</biblScope>
<biblScope unit="page-count">5</biblScope>
<publisher>Blackwell Publishing Ltd</publisher>
<pubPlace>Oxford, UK</pubPlace>
<date type="published" when="2004-10"></date>
</imprint>
</monogr>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><abstract xml:lang="en" style="main"><p><hi rend="bold">Summary. </hi>  
          von Willebrand disease is the most common inherited bleeding disorder in humans. VWD can be classified into three major types, designated Types 1, 2 and 3; Type 2 can be further separated into subtypes 2A, 2B, 2M and 2N. The diagnosis of VWD requires a personal and family history of bleeding and confirmation by laboratory analysis. Although Types 2 and 3 are relatively straightforward to diagnose, there may be a risk of overdiagnosis of Type 1 because of an overlap within the normal range. We also report on the clinical profile and diagnosis of VWD in a South American cohort of patients and on the <hi rend="italic">in vitro</hi>
 characteristics of some factor concentrates available for treatment of VWD.</p>
</abstract>
<textClass><keywords xml:lang="en"><term xml:id="k1">factor concentrate</term>
<term xml:id="k2">diagnosis</term>
<term xml:id="k3">treatment</term>
<term xml:id="k4">von Willebrand disease</term>
<term xml:id="k5">von Willebrand factor</term>
</keywords>
<keywords rend="tocHeading1"><term>von Willebrand Disease</term>
</keywords>
</textClass>
<langUsage><language ident="en"></language>
</langUsage>
</profileDesc>
</teiHeader>
</istex:fulltextTEI>
<json:item><extension>txt</extension>
<original>false</original>
<mimetype>text/plain</mimetype>
<uri>https://api.istex.fr/document/5380B00AA14E1F9E62415DC83D19AA5A8F69EBA5/fulltext/txt</uri>
</json:item>
</fulltext>
<metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration>
<istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Ltd</publisherName>
<publisherLoc>Oxford, UK</publisherLoc>
</publisherInfo>
<doi origin="wiley" registered="yes">10.1111/(ISSN)1365-2516</doi>
<issn type="print">1351-8216</issn>
<issn type="electronic">1365-2516</issn>
<idGroup><id type="product" value="HAE"></id>
<id type="publisherDivision" value="ST"></id>
</idGroup>
<titleGroup><title type="main" sort="HAEMOPHILIA">Haemophilia</title>
</titleGroup>
</publicationMeta>
<publicationMeta level="part" position="10000"><doi origin="wiley">10.1111/hae.2004.10.issue-s4</doi>
<numberingGroup><numbering type="journalVolume" number="10">10</numbering>
<numbering type="supplement">s4</numbering>
</numberingGroup>
<coverDate startDate="2004-10">October 2004</coverDate>
</publicationMeta>
<publicationMeta level="unit" type="article" position="29" status="forIssue"><doi origin="wiley">10.1111/j.1365-2516.2004.00979.x</doi>
<idGroup><id type="unit" value="HAE979"></id>
</idGroup>
<countGroup><count type="pageTotal" number="5"></count>
</countGroup>
<titleGroup><title type="tocHeading1">von Willebrand Disease</title>
</titleGroup>
<eventGroup><event type="firstOnline" date="2004-10-08"></event>
<event type="publishedOnlineFinalForm" date="2004-10-08"></event>
<event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-06"></event>
<event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-26"></event>
<event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-23"></event>
</eventGroup>
<numberingGroup><numbering type="pageFirst" number="164">164</numbering>
<numbering type="pageLast" number="168">168</numbering>
</numberingGroup>
<correspondenceTo>EJ Favaloro, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead NSW, 2145, Australia.
 Tel.: +(612) 9845 6618; fax: +(612) 9689 2331;
 e‐mail: <email>emmanuel@icpmr.wsahs.nsw.gov.au</email>
</correspondenceTo>
<linkGroup><link type="toTypesetVersion" href="file:HAE.HAE979.pdf"></link>
</linkGroup>
</publicationMeta>
<contentMeta><countGroup><count type="figureTotal" number="0"></count>
<count type="tableTotal" number="1"></count>
<count type="formulaTotal" number="0"></count>
<count type="referenceTotal" number="16"></count>
<count type="wordTotal" number="3233"></count>
<count type="linksPubMed" number="0"></count>
<count type="linksCrossRef" number="0"></count>
</countGroup>
<titleGroup><title type="main">von Willebrand disease: laboratory aspects of diagnosis and treatment</title>
<title type="shortAuthors">E. J. FAVALORO <i>et al.</i>
</title>
<title type="short">VWD: LABORATORY ASPECTS TO DIAGNOSIS AND TREATMENT</title>
</titleGroup>
<creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#aff-1-1"><personName><givenNames>E. J.</givenNames>
<familyName>Favaloro</familyName>
</personName>
</creator>
<creator creatorRole="author" xml:id="cr2" affiliationRef="#aff-1-1"><personName><givenNames>D.</givenNames>
<familyName>Lillicrap</familyName>
</personName>
</creator>
<creator creatorRole="author" xml:id="cr3" affiliationRef="#aff-1-1"><personName><givenNames>M. A.</givenNames>
<familyName>Lazzari</familyName>
</personName>
</creator>
<creator creatorRole="author" xml:id="cr4" affiliationRef="#aff-1-1"><personName><givenNames>M.</givenNames>
<familyName>Cattaneo</familyName>
</personName>
</creator>
<creator creatorRole="author" xml:id="cr5" affiliationRef="#aff-1-1"><personName><givenNames>C.</givenNames>
<familyName>Mazurier</familyName>
</personName>
</creator>
<creator creatorRole="author" xml:id="cr6" affiliationRef="#aff-1-1"><personName><givenNames>A.</givenNames>
<familyName>Woods</familyName>
</personName>
</creator>
<creator creatorRole="author" xml:id="cr7" affiliationRef="#aff-1-1"><personName><givenNames>S.</givenNames>
<familyName>Meschengieser</familyName>
</personName>
</creator>
<creator creatorRole="author" xml:id="cr8" affiliationRef="#aff-1-1"><personName><givenNames>A.</givenNames>
<familyName>Blanco</familyName>
</personName>
</creator>
<creator creatorRole="author" xml:id="cr9" affiliationRef="#aff-1-1"><personName><givenNames>A. C.</givenNames>
<familyName>Kempfer</familyName>
</personName>
</creator>
<creator creatorRole="author" xml:id="cr10" affiliationRef="#aff-1-1"><personName><givenNames>A.</givenNames>
<familyName>Hubbard</familyName>
</personName>
</creator>
<creator creatorRole="author" xml:id="cr11" affiliationRef="#aff-1-1"><personName><givenNames>A.</givenNames>
<familyName>Chang</familyName>
</personName>
</creator>
</creators>
<affiliationGroup><affiliation xml:id="aff-1-1" countryCode="US"><unparsedAffiliation>
            *Institute of Clinical Pathology and Medical Research, Australia
; 

            †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada
; 

            ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina
; 

            §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy
; 

            ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France
; 

            ††National Institute for Biological Standards and Control, UK
, and 

            ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA</unparsedAffiliation>
</affiliation>
</affiliationGroup>
<keywordGroup xml:lang="en"><keyword xml:id="k1">factor concentrate</keyword>
<keyword xml:id="k2">diagnosis</keyword>
<keyword xml:id="k3">treatment</keyword>
<keyword xml:id="k4">von Willebrand disease</keyword>
<keyword xml:id="k5">von Willebrand factor</keyword>
</keywordGroup>
<abstractGroup><abstract type="main" xml:lang="en"><p><b>Summary. </b>  
          von Willebrand disease is the most common inherited bleeding disorder in humans. VWD can be classified into three major types, designated Types 1, 2 and 3; Type 2 can be further separated into subtypes 2A, 2B, 2M and 2N. The diagnosis of VWD requires a personal and family history of bleeding and confirmation by laboratory analysis. Although Types 2 and 3 are relatively straightforward to diagnose, there may be a risk of overdiagnosis of Type 1 because of an overlap within the normal range. We also report on the clinical profile and diagnosis of VWD in a South American cohort of patients and on the <i>in vitro</i>
 characteristics of some factor concentrates available for treatment of VWD.</p>
</abstract>
</abstractGroup>
</contentMeta>
</header>
</component>
</istex:document>
</istex:metadataXml>
<mods version="3.6"><titleInfo lang="en"><title>von Willebrand disease: laboratory aspects of diagnosis and treatment</title>
</titleInfo>
<titleInfo type="abbreviated" lang="en"><title>VWD: LABORATORY ASPECTS TO DIAGNOSIS AND TREATMENT</title>
</titleInfo>
<titleInfo type="alternative" contentType="CDATA" lang="en"><title>von Willebrand disease: laboratory aspects of diagnosis and treatment</title>
</titleInfo>
<name type="personal"><namePart type="given">E. J.</namePart>
<namePart type="family">Favaloro</namePart>
<affiliation>*Institute of Clinical Pathology and Medical Research, Australia; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France; ††National Institute for Biological Standards and Control, UK, and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">D.</namePart>
<namePart type="family">Lillicrap</namePart>
<affiliation>*Institute of Clinical Pathology and Medical Research, Australia; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France; ††National Institute for Biological Standards and Control, UK, and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">M. A.</namePart>
<namePart type="family">Lazzari</namePart>
<affiliation>*Institute of Clinical Pathology and Medical Research, Australia; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France; ††National Institute for Biological Standards and Control, UK, and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">M.</namePart>
<namePart type="family">Cattaneo</namePart>
<affiliation>*Institute of Clinical Pathology and Medical Research, Australia; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France; ††National Institute for Biological Standards and Control, UK, and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">C.</namePart>
<namePart type="family">Mazurier</namePart>
<affiliation>*Institute of Clinical Pathology and Medical Research, Australia; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France; ††National Institute for Biological Standards and Control, UK, and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">A.</namePart>
<namePart type="family">Woods</namePart>
<affiliation>*Institute of Clinical Pathology and Medical Research, Australia; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France; ††National Institute for Biological Standards and Control, UK, and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">S.</namePart>
<namePart type="family">Meschengieser</namePart>
<affiliation>*Institute of Clinical Pathology and Medical Research, Australia; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France; ††National Institute for Biological Standards and Control, UK, and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">A.</namePart>
<namePart type="family">Blanco</namePart>
<affiliation>*Institute of Clinical Pathology and Medical Research, Australia; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France; ††National Institute for Biological Standards and Control, UK, and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">A. C.</namePart>
<namePart type="family">Kempfer</namePart>
<affiliation>*Institute of Clinical Pathology and Medical Research, Australia; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France; ††National Institute for Biological Standards and Control, UK, and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">A.</namePart>
<namePart type="family">Hubbard</namePart>
<affiliation>*Institute of Clinical Pathology and Medical Research, Australia; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France; ††National Institute for Biological Standards and Control, UK, and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">A.</namePart>
<namePart type="family">Chang</namePart>
<affiliation>*Institute of Clinical Pathology and Medical Research, Australia; †Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Canada; ‡Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Argentina; §University of Milano, Ospedale San Paolo, Unit di Hematologica, Italy; ¶Department of Preclinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, France; ††National Institute for Biological Standards and Control, UK, and ‡‡Center for Biologics Evaluation and Research, Food and Drug Administration, USA</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<typeOfResource>text</typeOfResource>
<genre type="article" displayLabel="article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</genre>
<originInfo><publisher>Blackwell Publishing Ltd</publisher>
<place><placeTerm type="text">Oxford, UK</placeTerm>
</place>
<dateIssued encoding="w3cdtf">2004-10</dateIssued>
<copyrightDate encoding="w3cdtf">2004</copyrightDate>
</originInfo>
<language><languageTerm type="code" authority="rfc3066">en</languageTerm>
<languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</language>
<physicalDescription><extent unit="figures">0</extent>
<extent unit="tables">1</extent>
<extent unit="formulas">0</extent>
<extent unit="references">16</extent>
<extent unit="linksCrossRef">0</extent>
<extent unit="words">3233</extent>
</physicalDescription>
<abstract>Summary.  von Willebrand disease is the most common inherited bleeding disorder in humans. VWD can be classified into three major types, designated Types 1, 2 and 3; Type 2 can be further separated into subtypes 2A, 2B, 2M and 2N. The diagnosis of VWD requires a personal and family history of bleeding and confirmation by laboratory analysis. Although Types 2 and 3 are relatively straightforward to diagnose, there may be a risk of overdiagnosis of Type 1 because of an overlap within the normal range. We also report on the clinical profile and diagnosis of VWD in a South American cohort of patients and on the in vitro characteristics of some factor concentrates available for treatment of VWD.</abstract>
<subject lang="en"><genre>keywords</genre>
<topic>factor concentrate</topic>
<topic>diagnosis</topic>
<topic>treatment</topic>
<topic>von Willebrand disease</topic>
<topic>von Willebrand factor</topic>
</subject>
<relatedItem type="host"><titleInfo><title>Haemophilia</title>
</titleInfo>
<genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre>
<identifier type="ISSN">1351-8216</identifier>
<identifier type="eISSN">1365-2516</identifier>
<identifier type="DOI">10.1111/(ISSN)1365-2516</identifier>
<identifier type="PublisherID">HAE</identifier>
<part><date>2004</date>
<detail type="volume"><caption>vol.</caption>
<number>10</number>
</detail>
<detail type="supplement"><caption>Suppl. no.</caption>
<number>s4</number>
</detail>
<extent unit="pages"><start>164</start>
<end>168</end>
<total>5</total>
</extent>
</part>
</relatedItem>
<identifier type="istex">5380B00AA14E1F9E62415DC83D19AA5A8F69EBA5</identifier>
<identifier type="ark">ark:/67375/WNG-CTNWQQNB-F</identifier>
<identifier type="DOI">10.1111/j.1365-2516.2004.00979.x</identifier>
<identifier type="ArticleID">HAE979</identifier>
<recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource>
<recordOrigin>Blackwell Publishing Ltd</recordOrigin>
</recordInfo>
</mods>
<json:item><extension>json</extension>
<original>false</original>
<mimetype>application/json</mimetype>
<uri>https://api.istex.fr/document/5380B00AA14E1F9E62415DC83D19AA5A8F69EBA5/metadata/json</uri>
</json:item>
</metadata>
<serie></serie>
</istex>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Istex/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F76 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000F76 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Istex
   |étape=   Corpus
   |type=    RBID
   |clé=     ISTEX:5380B00AA14E1F9E62415DC83D19AA5A8F69EBA5
   |texte=   von Willebrand disease: laboratory aspects of diagnosis and treatment
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

von Willebrand disease: laboratory aspects of diagnosis and treatment

von Willebrand disease: laboratory aspects of diagnosis and treatment

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri